Nextage Therapeutics (XTAE:NXTG) Debt-to-Revenue : 0.27 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nextage Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.31 Mil. Nextage Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.07 Mil. Nextage Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was ₪1.43 Mil. Nextage Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.27.

Nextage Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Nextage Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Debt-to-Revenue Chart

Nextage Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

3.87

4.40

14.80

N/A

0.43

Nextage Therapeutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial									N/A	N/A	N/A	1.71	0.27

Competitive Comparison of Nextage Therapeutics's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Debt-to-Revenue falls into.

Nextage Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nextage Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.308	+	0.07)	/	0.876
	=	0.43

Nextage Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.308	+	0.07)	/	1.426
	=	0.27

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Nextage Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextage Therapeutics (XTAE:NXTG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581

Website

http://www.m-medic.com

Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines

From GuruFocus

First Trust Global Portfolios Limited Announces Name Changes for Certain Sub-Funds of First Trust Global Funds plc

By Business Wire Business Wire • 01-29-2021